Protective antigen of epstein barr virus
AssigneeThe Rockefeller University
InventorsRalph Steinman, Christan Muenz
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4+ T cell response. The responsive CD4+ T cell are primarily TH1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.
Claims21
1-9. (canceled)
A method for protecting a subject from infection by Epstein Barr Virus, which method comprises delivering an immunologically effective amount of an immunogenic EBNA-1 polypeptide to the subject.
A method for protecting a subject from infection by Epstein Barr Virus comprising delivering an immuno-protective amount of an expression vector comprising a sequence encoding an immunogenic EBNA-1 polypeptide, operably associated with an expression control sequence.
20-35. (canceled)
A method for making an EBV-protective human dendritic cell, which method comprises contacting a human dendritic cell with a nucleic acid encoding an EBNA-1 polypeptide in humans.
Dependencies are inferred from the claim text.